Dr. Shih is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1800 Orleans Street
Baltimore, MD 21287Phone+1 410-955-5000Fax+1 410-955-5001
Education & Training
- Johns Hopkins University School of MedicinePost-Doctoral Fellowship, 1998 - 2000
- Johns Hopkins University School of MedicineFellowship, 1997 - 2000
- Johns Hopkins UniversityResidency, Pathology-Anatomic and Clinical, 1994 - 1997
- University of PennsylvaniaPhD, Biomedical Research, 1989 - 1993
- Taipei Medical UniversityClass of 1988
Certifications & Licensure
- MD State Medical License 1997 - 2025
- American Board of Pathology Anatomic Pathology
Publications & Presentations
PubMed
- LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker.Pamela R de Santiago, Sho Sato, Stephanie J Zhang, Meaghan C Dougher, Kyle M Devins
NPJ Precision Oncology. 2025-03-06 - 3 citationsEarly Genetic Divergence of High-Grade Carcinomas Originating from Low-Grade Serous Ovarian Neoplasms.M Herman Chui, Qianqian Song, Jiarun Zhu, Yuchen Jiao, Brant Wang
Modern Pathology. 2025-01-01 - Dual Inhibition of SYK and EGFR Overcomes Chemoresistance by Inhibiting CDC6 and Blocking DNA Replication.Jayaprakash Mandal, Tiffany Nicole Jones, Juliane Marie Liberto, Stephanie Gaillard, Tian-Li Wang
Cancer Research. 2024-11-15
Grant Support
- SPORE in Ovarian CancerJOHNS HOPKINS UNIVERSITY2018–2029
- SPORE in Ovarian CancerJOHNS HOPKINS UNIVERSITY2018–2029
- SPORE in Ovarian CancerJOHNS HOPKINS UNIVERSITY2018–2029
- A multidisciplinary BCC for ovarian cancer early detection: translating discoveries to clinical use with a by-design approachJOHNS HOPKINS UNIVERSITY2022–2027
- A multidisciplinary BCC for ovarian cancer early detection: translating discoveries to clinical use with a by-design approachJOHNS HOPKINS UNIVERSITY2022–2027
- A multidisciplinary BCC for ovarian cancer early detection: translating discoveries to clinical use with a by-design approachJOHNS HOPKINS UNIVERSITY2022–2027
- Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk womenJOHNS HOPKINS UNIVERSITY2021–2026
- Role of cancer-associated mutations in endometriosisJOHNS HOPKINS UNIVERSITY2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: